MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of William D. Humphries to its board of directors. Additionally, Justin Klein, M.D., J.D., is stepping down from his role as […]
Tag: PhaseBio
PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor
First 143 patients enrolled in the pivotal Phase 3 trial, with top-line results from interim analysis expected later this year Enrollment of patients in the REVERSE-IT trial requiring urgent surgery or invasive procedure now complete, with trial focus shifting to enrollment of patients with uncontrolled major or life-threatening bleeding Phase […]
PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
Entered exclusive licensing agreement with Alfasigma S.p.A with up to $245 million in milestone payments and tiered royalty payments for development and commercialization of bentracimab in European and other key markets Achieved interim enrollment milestone with first 143 bentracimab patients enrolled in the REVERSE-IT pivotal Phase 3 trial, with top-line […]
PhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for Bentracimab
Enrollment in the REVERSE-IT global Phase 3 trial from clinical sites in China expected to begin later in 2021 MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the Investigational New […]
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab
Agreement provides PhaseBio with $20 million upfront payment and eligibility to receive up to $245 million in development and commercial milestones in addition to tiered double digit royalties on sales Collaboration reinforces global bentracimab opportunity Establishes accessibility to bentracimab, if approved, for the largest pool of ticagrelor patients in the […]
PhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology’s 70th Annual Scientific Session
Study leveraging the IBM® MarketScan® claims database examined bleeding events and rates of surgical procedures in patients initiating P2Y12 inhibitors, FXa inhibitors or dabigatran Analyses revealed that patients receiving P2Y12 inhibitors had a higher burden of significant comorbid conditions at baseline than patients receiving FXa inhibitors or dabigatran Results demonstrate patients prescribed P2Y12 inhibitors […]
PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
Continued enrollment progress in Phase 3 REVERSE-IT clinical trial for Bentracimab Signed commercial supply agreement with BioVectra to support development and commercialization of lead product candidate bentracimab Completed underwritten public offering of common stock yielding $60.1 million in net proceeds May 13, 2021 04:00 PM Eastern Daylight Time MALVERN, Pa. […]
PhaseBio Announces Pricing of Public Offering of Common Stock
MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock at a public offering price of $3.50 per […]
PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
Provides overview of bentracimab development program during virtual Investor & Analyst Day, March 15, 2021, 12 – 2 pm ET Announced commercial supply agreement with BioVectra to support the development and commercialization of lead product candidate bentracimab Expanded pivotal Phase 3 REVERSE-IT trial of bentracimab into Canada and the European […]
PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab
MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a commercial scale supply agreement for the production of bentracimab, PhaseBio’s […]
Recent
Popular
- No commented posts yet